Toward more focused multimodal and multidisciplinary approaches for pain management in Parkinson’s disease

References

• Skogar O, Lokk J. Pain management in patients with Parkinson’s disease: challenges and solutions. J Multidiscip Healthc. 2016;9:469–479. doi:10.2147/JMDH.S10585727757037
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al.; PRIAMO study group. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649. doi:10.1002/mds.2264319514014
   PubMed Web of Science ®Google Scholar
• Broen MP, Braaksma MM, Patijn J, Weber WE. Prevalence of pain in Parkinson’s disease: a systematic review using the modified QUADAS tool. Mov Disord. 2012;27:480–484. doi:10.1002/mds.2405422231908
   PubMed Web of Science ®Google Scholar
• Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017;124(8):901–905. doi:10.1007/s00702-017-1686-y28150045
   PubMed Web of Science ®Google Scholar
• Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O; DoPaMiP Study Group. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23(10):1361–1369. doi:10.1002/mds.2214218546344
   PubMed Web of Science ®Google Scholar
• Sophie M, Ford B. Management of pain in Parkinson’s disease. CNS Drugs. 2012;26(11):937–948. doi:10.1007/s40263-012-0005-223055368
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Odin P, Antonini A, Martinez-Martin P. Parkinson’s disease: the non-motor issues. Parkinsonism Relat Disord. 2011;17:717–723. doi:10.1016/j.parkreldis.2011.02.01821741874
   PubMed Web of Science ®Google Scholar
• Rana AQ, Qureshi ARM, Kachhvi HB, Rana MA, Chou KL. Increased likelihood of anxiety and poor sleep quality in Parkinson’s disease patients with pain. J Neurol Sci. 2016;369:212–215. doi:10.1016/j.jns.2016.07.06427653891
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, et al. The nondeclaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord. 2010;25:704–709. doi:10.1002/mds.2286820437539
   PubMed Web of Science ®Google Scholar
• Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson’s disease: prevalence and characteristics. Pain. 2009;141(1–2):173–177. doi:10.1016/j.pain.2008.12.00419100686
   PubMed Web of Science ®Google Scholar
• Quittenbaum BH, Grahn B. Quality of life and pain in Parkinson’s disease: a controlled cross-sectional study. Parkinsonism Relat Disord. 2004;10(3):129–136. doi:10.1016/j.parkreldis.2003.12.00115036166
   PubMed Web of Science ®Google Scholar
• Madden MB, Hall DA. Shoulder pain in Parkinson’s disease: a case-control study. Mov Disord. 2010;25(8):1105–1106. doi:10.1002/mds.2304820222136
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord. 2006;21(7):916–923. doi:10.1002/mds.2084416547944
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Rizos A, Trenkwalder C, et al.; EUROPAR and the IPMDS Non Motor PD Study Group. King’s Parkinson’s disease pain scale, the first scale for pain in PD: an international validation. Mov Disord. 2015;30(12):1623–1631. doi:10.1002/mds.2627026096067
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Rizos AM, Wetmore J, et al.; EUROPAR and MDS Non-motor PD Study Group. First comprehensive tool for screening pain in Parkinson’s disease: the King’s Parkinson’s disease pain questionnaire. Eur J Neurol. 2018;25(10):1255–1261. doi:10.1111/ene.1369129806962
   PubMed Web of Science ®Google Scholar
• Etchepare F, Rozenberg S, Mirault T, et al. Back problems in Parkinson’s disease: an underestimated problem. Joint Bone Spine. 2006;73(3):298–302. doi:10.1016/j.jbspin.2005.05.00616376599
   PubMed Web of Science ®Google Scholar
• Broetz D, Eichner M, Gasser T, Weller M, Steinbach JP. Radicular and nonradicular back pain in Parkinson’s disease: a controlled study. Mov Disord. 2007;22(6):853–856. doi:10.1002/mds.2143917357131
   PubMed Web of Science ®Google Scholar
• Defazio G, Berardelli A, Fabbrini G, et al. Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol. 2008;65(9):1191–1194. doi:10.1001/archneurol.2008.218779422
   PubMedGoogle Scholar
• Ehrt U, Larsen JP, Aarsland D. Pain and its relationship to depression in Parkinson disease. Am J Geriatr Psychiatry. 2009;17(4):269–275.19322934
   PubMed Web of Science ®Google Scholar
• Kubo S, Hamada S, Maeda T, et al. A Japanese multicenter survey characterizing pain in Parkinson’s disease. J Neurol Sci. 2016;365:162–166. doi:10.1016/j.jns.2016.04.01527206899
   PubMed Web of Science ®Google Scholar
• Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol. 2006;6:9. doi:10.1186/1471-2288-6-916519814
   PubMedGoogle Scholar
• Defazio G, Tinazzi M, Berardelli A. How pain arises in Parkinson’s disease? Eur J Neurol. 2013;20(12):1517–1523. doi:10.1111/ene.1226024118186
   PubMed Web of Science ®Google Scholar
• Ford B. Pain in Parkinson’s disease. Mov Disord. 2010;25:S98–S103. doi:10.1002/mds.2271620187254
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L, Carli G, Casoni F, Galbiati A. Restless legs syndrome and Parkinson disease: a causal relationship between the two disorders? Front Neurol. 2018;9:551. doi:10.3389/fneur.2018.0055130087647
   PubMed Web of Science ®Google Scholar
• Lin XJ, Yu N, Lin XG, et al. A clinical survey of pain in Parkinson’s disease in Eastern China. Int Psychogeriatr. 2016;28(2):283–289. doi:10.1017/S104161021500165926443237
   PubMed Web of Science ®Google Scholar
• Oshima H, Katayama Y, Morishita T, et al. Subthalamic nucleus stimulation for attenuation of pain related to Parkinson disease. J Neurosurg. 2012;116(1):99–106. doi:10.3171/2011.7.JNS1115821905799
   PubMed Web of Science ®Google Scholar
• Yardimci N, Cemeroglu O, Ozturk E, et al. Median and ulnar neuropathy assessment in Parkinson’s disease regarding symptom severity and asymmetry. Parkinsons Dis. 2016;2016:4958068. doi:10.1155/2016/495806827843673
   PubMed Web of Science ®Google Scholar
• Tinazzi M, Del Vesco C, Fincati E, et al. Pain and motor complication in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2009;77:822–825. doi:10.1136/jnnp.2005.079053
   Web of Science ®Google Scholar
• Kosek E, Cohen M, Baron R, et al. Do we need a third mechanistic descriptor for chronic pain states? Pain. 2016;157:1382–1386. doi:10.1097/j.pain.000000000000047326835783
   PubMed Web of Science ®Google Scholar
• Romagnolo A, Merola A, Artusi CA, Rizzone MG, Zibetti M, Lopiano L. Levodopa-induced neuropathy: a systematic review. Mov Disord Clin Pract. 2018;6(2):96–103. doi:10.1002/mdc3.1268830838307
   PubMed Web of Science ®Google Scholar
• Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry. 2015;86(5):490–495. doi:10.1136/jnnp-2014-30858625168395
   PubMed Web of Science ®Google Scholar
• Valkovic P, Minar M, Singliarova H, et al. Pain in Parkinson’s disease: a cross-sectional study of its prevalence, types, and relationship to depression and quality of life. PLoS One. 2015;10(8):e0136541. doi:10.1371/journal.pone.013654126309254
   PubMed Web of Science ®Google Scholar
• Schestatsky P, Kumru H, Valls-Solé J, et al. Neurophysiologic study of central pain in patients with Parkinson disease. Neurology. 2007;69(23):2162–2169. doi:10.1212/01.wnl.0000295669.12443.d318056580
   PubMed Web of Science ®Google Scholar
• Cuomo A, Bimonte S, Forte CA, Botti G, Cascella M. Multimodal approaches and tailored therapies for pain management: the trolley analgesic model. J Pain Res. 2019;12:711–714. doi:10.2147/JPR.S17891030863143
   PubMed Web of Science ®Google Scholar
• Markman JD, Jensen TS, Semel D, et al. Effects of pregabalin in patients with neuropathic pain previously treated with gabapentin: a pooled analysis of parallel-group, randomized, placebo-controlled clinical trials. Pain Pract. 2017;17:718–728. doi:10.1111/papr.1255027611736
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162–173. doi:10.1016/S1474-4422(14)70251-025575710
   PubMed Web of Science ®Google Scholar
• Cruccu G, Sommer C, Anand P, et al. EFNS guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol. 2010;17:1010–1018. doi:10.1111/j.1468-1331.2010.02969.x20298428
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE). Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings. 2013 [Update 4 2018]. Available from: https://www.nice.org.uk/guidance/cg173. Accessed 214, 2019
   Google Scholar
• Singh R. Tramadol-induced parkinsonism: a case report of a 75-year-old woman. J Basic Clin Physiol Pharmacol. 2018;30:275–278. doi:10.1515/jbcpp-2018-011330447142
   PubMedGoogle Scholar
• Cruccu G, Truini A. A review of neuropathic pain: from guidelines to clinical practice. Pain Ther. 2017;6(Suppl 1):35–42. doi:10.1007/s40122-017-0087-029178033
   PubMed Web of Science ®Google Scholar
• Lowin J, Sail K, Baj R, et al. The cost-effectiveness of levodopa/carbidopa intestinal gel compared to standard care in advanced Parkinson’s disease. J Med Econ. 2017;20(11):1207–1215. doi:10.1080/13696998.2017.137941128895769
   PubMed Web of Science ®Google Scholar
• Ren L, Yi J, Yang J, Li P, Cheng X, Mao P. Nonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: a dose-response meta-analysis. Medicine (Baltimore). 2018;97(37):e12172. doi:10.1097/MD.000000000001217230212946
   PubMed Web of Science ®Google Scholar
• American Parkinson Disease Association. Medications to be avoided or used with caution in Parkinson’s disease. Available from: https://www.apdaparkinson.org/wp-content/uploads/2018/05/APDA-Meds_to_Avoid.pdf. Accessed 22, 2019.
   Google Scholar
• Yan T, Rizak JD, Yang S, et al. Acute morphine treatments alleviate tremor in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys. PLoS One. 2014;9(2):e88404 Published 2014 Feb 10. doi:10.1371/journal.pone.008840424520383
   PubMed Web of Science ®Google Scholar
• Samadi P, Grégoire L, Bédard PJ. The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiol Dis. 2004;16(1):246–253. doi:10.1016/j.nbd.2004.02.00215207281
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Chaudhuri KR, Martinez-Martin P, et al.; PANDA study group. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015;14(12):1161–1170. doi:10.1016/S1474-4422(15)00243-426494524
   PubMed Web of Science ®Google Scholar
• Antonini A, Tinazzi M. Targeting pain in Parkinson’s disease. Lancet Neurol. 2015;14(12):1144–1145. doi:10.1016/S1474-4422(15)00286-026494525
   PubMed Web of Science ®Google Scholar
• Madeo G, Schirinzi T, Natoli S, et al. Efficacy and safety profile of prolonged release oxycodone in combination with naloxone (OXN PR) in Parkinson’s disease patients with chronic pain. J Neurol. 2015;262(9):2164–2170. doi:10.1007/s00415-015-7823-326134157
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Hauser RA, Freeman A, Sullivan KL, Miller AM, Halim T. Fentanyl-induced bradykinesia and rigidity after deep brain stimulation in a patient with Parkinson disease. Clin Neuropharmacol. 2009;32(1):48–50. doi:10.1097/WNF.0b013e31817e23e319471184
   PubMed Web of Science ®Google Scholar
• Cascella M, Forte CA, Bimonte S, et al. Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study. J Pain Res. 2018;12:117–125. eCollection 2019. doi:10.2147/JPR.S18107930613160
   PubMed Web of Science ®Google Scholar
• Abrams SB, Hallett M. Clinical utility of different botulinum neurotoxin preparations. Toxicon. 2013;67:81–86. doi:10.1016/j.toxicon.2012.11.02423375537
   PubMed Web of Science ®Google Scholar
• Jung YJ, Kim HJ, Jeon BS, Park H, Lee WW, Paek SH. An 8-year follow-up on the effect of subthalamic nucleus deep brain stimulation on pain in parkinson disease. JAMA Neurol. 2015;72:504–510. doi:10.1001/jamaneurol.2015.825799451
   PubMed Web of Science ®Google Scholar
• Honey CR, Stoessl AJ, Tsui JK, Schulzer M, Calne DB. Unilateral pallidotomy for reduction of parkinsonian pain. J Neurosurg. 1999;91:198–201. doi:10.3171/jns.1999.91.2.019810433307
   PubMed Web of Science ®Google Scholar
• Loher TJ, Burgunder JM, Weber S, Sommerhalder R, Krauss JK. Effect of chronic pallidal deep brain stimulation on off period dystonia and sensory symptoms in advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:395–399. doi:10.1136/jnnp.73.1.7612235307
   PubMed Web of Science ®Google Scholar
• Hassan S, Amer S, Alwaki A, Elborno A. A patient with Parkinson’s disease benefits from spinal cord stimulation. J Clin Neurosci. 2013;20(8):1155–1156. doi:10.1016/j.jocn.2012.08.01823453160
   PubMed Web of Science ®Google Scholar